Resolution of RSMSIM expert council «State and prospects of pneumococcal vaccination in the Russian Federation»

Cover Page

Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Vaccination is one of the priority areas in the implementation of the national policy for the development of the healthcare system, including the priority national project "Health", the program "Prevention and control of socially significant diseases", aimed at protecting Russian citizens from vaccine-preventable infections by improving the National Immunization Schedule (NCV). ) and the implementation of the "Strategy for the development of immunoprophylaxis of infectious diseases until 2035".

Full Text

Restricted Access

References

  1. Decree «On national goals and strategic objectives of the development of the Russian Federation for the period up to 2030». URL: http://www.consultant.ru/law/hotdocs/63714.html (date of access – 01.05.2023) (In Russ.).
  2. Strategy for the development of immunoprophylaxis of infectious diseases for the period up to 2035 (with annex) on 21 pages. Approved by order of the Government of the Russian Federation of September 18, 2020 No. 2390-r (In Russ.).
  3. Action plan for the implementation of the Strategy for the development of immunoprophylaxis of infectious diseases for the period up to 2035, approved by the Government of the Russian Federation on 03/29/21. №774-r (In Russ.).
  4. -valent pneumococcal polysaccharide vaccine. WHO position paper. Wkly Epidemiol Rec. 2008; 83(42): 373–84.
  5. Data of Federal State Statistics Service, 2017–2018 (In Russ.).
  6. Guidelines for clinical immunology in respiratory medicine (2nd edition, revised). Ed. by Kostinova M.P., Chuchalin A.G. Moscow: MDV Group. 2018; 304 pp. (In Russ.). ISBN: 978-5-906748-08-9. EDN: XMJKMH.
  7. Koroleva I.S. Information and analytical review «Meningococcal infection and purulent bacterial meningitis in the Russian Federation 2017». Moscow: Central Research Institute of Epidemiology of Rospotrebnadzor. 2017 (In Russ.).
  8. Data of statistical materials of the Central Research Institute of Organization and Informatization of Healthcare of the Ministry of Healthcare of Russia «Medical and demographic indicators of the Russian Federation». URL: https://rosstat.gov.ru/storage/mediabank/BgjLrP31/demogr_01-06.pdf (date of access – 01.05.2023) (In Russ.).
  9. Kyaw M.H., Rose C.E. Jr., Fry A.M. et al. The influence of chronic illnesses on the incidence of invasive pneumococcal disease in adults. J Infect Dis. 2005; 192(3) :377–86. https://dx.doi.org/10.1086/431521.
  10. Tarasova A.A., Kostinov M.P., Paramonova Yu.A. Approaches to vaccine prophilaxis of respiratory infections in patients with diabetes mellitus in the modern epidemiological situation. Sakharnyy diabet = Diabetes Mellitus. 2019; 22(5): 473–480 (In Russ.). https://dx.doi.org/10.14341/DM9820. EDN: DWGDFI.
  11. Kulikov P.V., Zhogolev S.D., Aminev R.M. et al. Epidemiological and etiological characteristics of community-acquired pneumonia in conscripts in the modern period. comparative evaluation of the effectiveness of Pneumococcal vaccines. Zhurnal infektologii = Journal of Infectology. 2019; 11(2): 116–123 (In Russ.). https://dx.doi.org/10.22625/2072-6732-2019-11-2-116-123. EDN: CQWBCG.
  12. Metersky M.L., Masterton R.G., Lode H. et al. Epidemiology, microbiology, and treatment considerations for bacterial pneumonia complicating influenza. Int J Infect Dis. 2012; 16(5): e321–31. https://dx.doi.org/10.1016/j.ijid.2012.01.003.
  13. Bonten M.J., Huijts S.M., Bolkenbaas M. et al. Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults. N EnglJ Med. 2015; 372(12): 1114–25. https://dx.doi.org/10.1056/NEJMoa1408544.
  14. Kurkova A.A., Muraviov A.A., Kozlov R.S. The current status of antimicrobial resistance of Streptococcus pneumonia and specific vaccine prevention of pneumococcal infection. Pulmonologiya = Pulmonology. 2022; 3655 (In Russ.). https://dx.doi.org/10.18093/0869-0189-2022-3655.
  15. McLaughlin J.M., Jiang Q., Isturiz R.E. et al. Effectiveness of 13-valent pneumococcal conjugate vaccine against hospitalization for community-acquired pneumonia in older US adults: A test-negative design. Clin Infect Dis. 2018; 67(10): 1498–506. https://dx.doi.org/10.1093/cid/ciy312.
  16. Ignatova G.L., Antonov V.N. Efficiency of vaccine prophylaxis concentrated pneumococcal vaccine in patients with chronic obstructive lung disease and chronic heart failure. Terapevticheskiy arkhiv = Therapeutic Archive. 2018; 90(8): 53–62 (In Russ.). https://dx.doi.org/10.26442/terarkh201890853-62. EDN: XVYHGH.
  17. Rudakova A.V., Briko N.I., Lobzin Yu.V. et al. Vaccination against Pneumococcal infections in Russian Federation: social and pharmacoeconomic aspects. Zhurnal infektologii = Journal of Infectology. 2018; 10(3): 11–22 (In Russ.). https://dx.doi.org/10.22625/2072-6732-2018-10-3-11-22. EDN: YOQYXB.
  18. Rudakova A.V., Briko N.I., Lobzin Yu.V. et al. Cost-effectiveness of Pneumococcal vaccination among patients with diabetes mellitus. Epidemiologiya i vaktsinoprofilaktika = Epidemiology and Vaccination. 2022; 21(5): 78–88 (In Russ.). https://dx.doi.org/10.31631/2073-3046-2022-21-5-78-88. EDN: CDSEYU.
  19. Report on the conducted pharmacoeconomic study on the topic: «Pharmacoeconomic evaluation of vaccination of adult patients at risk with pneumococcal conjugate 13-valent vaccine (PCV13) in the Russian Federation». Cost-effectiveness assessment and impact on the budget of vaccination with pneumococcal vaccines, including PCV13, in adult patients with CHF» 10/29/2021. Saint Petersburg Chemical and Pharmaceutical University of the Ministry of Healthcare of Russia (In Russ.).

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2023 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies